Opendata, web and dolomites

INCENTIVE SIGNED

Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "INCENTIVE" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 19˙965˙992 €
 EC max contribution 9˙974˙293 € (50%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 2˙537˙797.00
2    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 1˙003˙785.00
3    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 919˙943.00
4    STICHTING HUMAN VACCINES PROJECT EUROPE NL (CASTRICUM) participant 794˙312.00
5    HUMAN VACCINES PROJECT, INC US (WILMINGTON NEW CASTLE) participant 760˙705.00
6    UNIVERSITE LIBRE DE BRUXELLES BE (BRUXELLES) participant 614˙963.00
7    UGA RESEARCH FOUNDATION INC NON PROFIT CORP US (ATHENS) participant 586˙990.00
8    UNIVERSITETET I BERGEN NO (BERGEN) participant 567˙296.00
9    BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE FR (LYON) participant 531˙858.00
10    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 441˙260.00
11    ASA SPEZIALENZYME GMBH DE (WOLFENBUTTEL) participant 387˙750.00
12    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 383˙670.00
13    UNIVERSITETET I OSLO NO (OSLO) participant 307˙086.00
14    EUROVACC FOUNDATION CH (LAUSANNE) participant 136˙875.00
15    INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IITM) IN (Chennai) participant 0.00
16    NATIONAL INSTITUTE OF IMMUNOLOGY SOCIETY IN (NEW DELHI) participant 0.00
17    PUBLIC HEALTH FOUNDATION OF INDIA IN (NEW DELHI) participant 0.00
18    SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY IN (MUMBAI) participant 0.00
19    TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE IN (FARIDABAD) participant 0.00

Map

 Project objective

The highly integrated INCENTIVE consortium represents true partnership between Indian and European/US groups that addresses the global health and economic challenge posed by influenza infections, to reduce the worldwide burden resulting from outbreaks. INCENTIVE’s strategic goals are to provide seminal knowledge on the underlying mechanisms of poor responsiveness to influenza vaccines in vulnerable individuals and advance the development of two next generation universal influenza vaccines. This is achieved by pursing the following specific objectives: 1) address the current knowledge gap by performing comprehensive immunome profiling of responders and non-responders to licensed influenza vaccines in infants, children, adults and elderly in parallel phase IV trials in Europe and India to identify the underlying mechanisms of vaccine responsiveness in different vulnerable populations and ethnical groups; 2) advance the development of two next generation universal vaccines, including an antigen presenting cell-targeted nucleic acid vaccine up to proof-of-concept for vaccine efficacy in non-human primates, and a computationally-derived second generation COBRA (Computationally-Optimized Broadly-Reactive Antigens) vaccine up to clinical development, comprising a phase I trial in Europe, a phase II trial in India and efficacy studies using an influenza controlled human challenge model; 3) identify predictive biomarkers of responsiveness to vaccination to develop new diagnostics; 4) implement comprehensive technology transfer and harmonization activities for immunological analysis and data integration; and 5) perform a health systems and investment analysis, and discrete choice experiments to assess the suitability of the developed technologies for low- and middle-income countries and to identify potential downstream constraints that might affect uptake by health care systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INCENTIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INCENTIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

ONCOBIOME (2019)

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Read More